Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

8.05USD
10:53pm IST
Change (% chg)

$-0.40 (-4.73%)
Prev Close
$8.45
Open
$8.45
Day's High
$8.50
Day's Low
$8.01
Volume
190,468
Avg. Vol
139,117
52-wk High
$15.51
52-wk Low
$7.42

Chart for

About

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of... (more)

Overall

Beta: --
Market Cap(Mil.): $377.79
Shares Outstanding(Mil.): 33.23
Dividend: --
Yield (%): --

Financials

BRIEF-Bellicum Enters Into Agreement With Oxford Finance To Borrow $35 Mln - SEC Filing

* BELLICUM PHARMACEUTICALS SAYS ENTERED INTO AGREEMENT WITH OXFORD FINANCE LLC TO BORROW $35.0 MILLION IN A SINGLE TERM LOAN - SEC FILING Source text: (http://bit.ly/2BhY3X0) Further company coverage:

22 Dec 2017

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​

08 Nov 2017

BRIEF-Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas

* Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas

16 Aug 2017

BRIEF-Bellicum Pharmaceuticals qtrly loss per share $0.74

* Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update

09 Aug 2017

Earnings vs. Estimates